-$1.68 EPS Expected for bluebird bio, Inc. (NASDAQ:BLUE) This Quarter

Wall Street analysts expect bluebird bio, Inc. (NASDAQ:BLUE) to announce ($1.68) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for bluebird bio’s earnings. The lowest EPS estimate is ($2.68) and the highest is ($0.95). bluebird bio reported earnings of ($3.01) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 44.2%. The company is expected to issue its next quarterly earnings report on Tuesday, February 22nd.

On average, analysts expect that bluebird bio will report full-year earnings of ($11.14) per share for the current financial year, with EPS estimates ranging from ($11.53) to ($10.74). For the next financial year, analysts forecast that the business will post earnings of ($5.78) per share, with EPS estimates ranging from ($11.14) to ($1.90). Zacks’ earnings per share averages are an average based on a survey of analysts that cover bluebird bio.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Friday, November 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($2.65) by ($0.51). bluebird bio had a negative return on equity of 76.93% and a negative net margin of 1,610.78%. The business had revenue of $22.70 million for the quarter, compared to the consensus estimate of $39.07 million. During the same period in the prior year, the business earned ($2.94) earnings per share. bluebird bio’s revenue was up 17.6% compared to the same quarter last year.

A number of analysts recently issued reports on the company. Wedbush lowered their target price on bluebird bio from $22.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, November 8th. Wells Fargo & Company lowered their price target on bluebird bio from $25.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Monday, November 8th. Morgan Stanley downgraded bluebird bio from an “equal weight” rating to an “underweight” rating and set a $11.00 price objective for the company. in a report on Monday, November 8th. Berenberg Bank reaffirmed a “hold” rating and set a $11.00 price target on shares of bluebird bio in a research report on Friday, November 12th. Finally, Stifel Nicolaus cut their price target on shares of bluebird bio from $31.00 to $18.00 and set a “hold” rating for the company in a research note on Monday, August 9th. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $18.75.

BLUE traded up $0.03 during trading hours on Thursday, hitting $10.76. 4,614,857 shares of the company’s stock were exchanged, compared to its average volume of 1,633,104. The stock has a market cap of $754.35 million, a price-to-earnings ratio of -0.84 and a beta of 1.58. bluebird bio has a 1-year low of $10.21 and a 1-year high of $53.68. The stock’s 50-day moving average is $17.80 and its two-hundred day moving average is $23.38.

Several institutional investors and hedge funds have recently made changes to their positions in BLUE. Berman Capital Advisors LLC raised its position in shares of bluebird bio by 3,217.0% in the third quarter. Berman Capital Advisors LLC now owns 1,758 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 1,705 shares in the last quarter. Lazard Asset Management LLC increased its stake in bluebird bio by 4,861.3% during the 2nd quarter. Lazard Asset Management LLC now owns 3,076 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 3,014 shares during the period. Point72 Hong Kong Ltd raised its holdings in bluebird bio by 130.5% in the 3rd quarter. Point72 Hong Kong Ltd now owns 6,474 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 3,665 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of bluebird bio during the 2nd quarter valued at $169,000. Finally, AGF Investments Inc. acquired a new stake in shares of bluebird bio during the 3rd quarter worth $199,000. 77.66% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.

See Also: Google Finance

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.